Jefferies analyst Akash Tewari said last year the dosing was beneficial since physicians have to forecast an infant's potential weight during RSV season with Sanofi and AstraZeneca's Beyfortus - the only preventive shot for RSV available in the country for infants and toddlers so far - which makes dose ordering and inventory more complex. Read more: https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/us-fda-approves-mercks-rsv-antibody-for-infants/121740373